References
- Rybak M. The pharmacokinetic profile of a new generation of parenteral cephalosporin. Am J Med 1996;100(6A):39S–44S.
- Garces EO, Andrade de Anzambuja MF, da Silva D, Bragatti JA, Jacoby T, Saldanha Thome F. Renal failure is a risk factor for cefepime-induced encephalopathy. J Nephrol 2008;21: 526–34.
- Neu HC. Safety of cefepime: a new extended-spectrum parenteral cephalosporin. Am J Med 1996;100(6A): 68S–75S.
- Gilbert DN. The Sanford guide to antimicrobial therapy 2011. Sperryville, VA: Antimicrobial Therapy, Inc.; 2011.
- Fawcett T. An introduction to ROC analysis. Pattern Recogn Lett 2006;27:861–74.
- Chow KM, Szeto CC, Hui AC, Wong TY, Li PK. Retrospective review of neurotoxicity induced by cefepime and ceftazidime. Pharmacotherapy 2003;23:369–73.
- Jallon P, Fankhauser L, Du Pasquier R, Coeytaux A, Picard F, Hefft S, et al. Severe but reversible encephalopathy associated with cefepime. Neurophysiol Clin 2000;30:383–6.
- Martinez-Rodriguez JE, Barriga FJ, Santamaria J, Iranzo A, Pareja JA, Revilla M, et al. Nonconvulsive status epilepticus associated with cephalosporins in patients with renal failure. Am J Med 2001;111:115–9.
- Grill MF, Maganti R. Cephalosporin-induced neurotoxicity: clinical manifestations, potential pathogenic mechanisms, and the role of electroencephalographic monitoring. Ann Pharmacother 2008;42:1843–50.
- Golik MV, Lawrence KR. Comparison of dosing recommendations for antimicrobial drugs based on two methods for assessing kidney function: Cockcroft–Gault and modification of diet in renal disease. Pharmacotherapy 2008;28:1125–32.
- Gangireddy VG, Mitchell LC, Coleman T. Cefepime neurotoxicity despite renal adjusted dosing. Scand J Infect Dis 2011;43:827–9.
- Barbhaiya RH, Knupp CA, Forgue ST, Matzke GR, Guay DR, Pittman KA. Pharmacokinetics of cefepime in subjects with renal insufficiency. Clin Pharmacol Ther 1990;48:268–76.
- Schmaldienst S, Traunmuller F, Burgmann H, Rosenkranz AR, Thalhammer-Scherrer R, Horl WH, et al. Multiple-dose pharmacokinetics of cefepime in long-term hemodialysis with high-flux membranes. Eur J Clin Pharmacol 2000;56: 61–4.
- Lamoth F, Buclin T, Pascual A, Vora S, Bolay S, Decosterd LA, et al. High cefepime plasma concentrations and neurological toxicity in febrile neutropenic patients with mild impairment of renal function. Antimicrob Agents Chemother 2010;54:4360–7.
- Lin CJ, Chen SP, Wang SJ, Fuh JL. Cefepime-related encephalopathy in peritoneal dialysis patients. J Chin Med Assoc 2011;74:87–90.
- Herishanu YO, Zlotnik M, Mostoslavsky M, Podgaietski M, Frisher S, Wirguin I. Cefuroxime-induced encephalopathy. Neurology 1998;50:1873–5.
- Sonck J, Laureys G, Verbeelen D. The neurotoxicity and safety of treatment with cefepime in patients with renal failure. Nephrol Dial Transplant 2008;23:966–70.
- Chapuis TM, Giannoni E, Majcherczyk PA, Chiolero R, Schaller MD, Berger MM, et al. Prospective monitoring of cefepime in intensive care unit adult patients. Crit Care 2010;14:R51.
- Maganti R, Jolin D, Rishi D, Biswas A. Nonconvulsive status epilepticus due to cefepime in a patient with normal renal function. Epilepsy Behav 2006;8:312–4.